CV Sciences Inc (OTCMKTS:CVSI) On Declining Spree

Continuing with the decline of last week, in the last trading session the stock price of CV Sciences Inc (OTCMKTS:CVSI) declined more than 1% to close the day at $0.260. The decline came at a share volume of 223,503 compared to average share volume of 350,768. The company exhibited and presented at the National University of Natural Medicine’s 2017 Medical Cannabis Conference from July 29 to July 30, 2017, in Portland, as Lead Sponsor.

The details

NUNM conference attendees were requested to a special lunch lecture on adrenal health, stress and hemp-derived Cannabinoid, hosted by renowned naturopathic physician and CV Sciences’ Medical Advisor, Dr. Aimée Shunney, on July 30. Dr. Shunney was expected to provide an engaging assessment of the growing evidence on the role of hemp-derived Cannabinoid and phytocannabinoids to advance healthy adrenal activity throughout life. The lecture helped attendees to discover the interactions of the human endocannabinoid system and CBD as it links to human health, and the prospective clinical uses for primary care, safety as well as plant-drug interaction data, and sourcing, quality and dosing.

Earlier to lecture, Dr Shunney reported that as a Medical Advisor to CV Sciences and a proud alum from NUNM, he is thrilled and honored to have the prospect to share his clinical experience with hemp-based Cannabinoid at the NUNM event. Being a naturopathic physician, he has a passion for discovering new modalities in his treatment protocols to resolve stress resilience for quality of life and chronic disease risk reduction. The addition of hemp-derived Cannabinoid to his toolbox has literally changed his ability to help his patients fight the effects of stress, sleep better and stabilize mood.

CV Sciences had arranged for a booth at conference, where the experts answered about the queries related to PlusCBD Oil™, and also distributed the free samples to attendees.

Christian Brown

Christian Brown

Christian is a keen follower of stock market and has been writing on the U.S based companies since past 7 years.